nodes	percent_of_prediction	percent_of_DWPC	metapath
Brimonidine—AOX1—Methotrexate—multiple sclerosis	0.347	1	CbGbCtD
Brimonidine—Eye disorder—Methylprednisolone—multiple sclerosis	0.000691	0.00108	CcSEcCtD
Brimonidine—Shock—Mitoxantrone—multiple sclerosis	0.000687	0.00108	CcSEcCtD
Brimonidine—Cardiac disorder—Methylprednisolone—multiple sclerosis	0.000687	0.00108	CcSEcCtD
Brimonidine—Bradycardia—Betamethasone—multiple sclerosis	0.000685	0.00107	CcSEcCtD
Brimonidine—Bradycardia—Dexamethasone—multiple sclerosis	0.000685	0.00107	CcSEcCtD
Brimonidine—Tachycardia—Mitoxantrone—multiple sclerosis	0.000682	0.00107	CcSEcCtD
Brimonidine—Skin disorder—Mitoxantrone—multiple sclerosis	0.000678	0.00106	CcSEcCtD
Brimonidine—Angiopathy—Methylprednisolone—multiple sclerosis	0.000671	0.00105	CcSEcCtD
Brimonidine—Rash—Cladribine—multiple sclerosis	0.00067	0.00105	CcSEcCtD
Brimonidine—Dermatitis—Cladribine—multiple sclerosis	0.000669	0.00105	CcSEcCtD
Brimonidine—Immune system disorder—Methylprednisolone—multiple sclerosis	0.000668	0.00105	CcSEcCtD
Brimonidine—Mediastinal disorder—Methylprednisolone—multiple sclerosis	0.000667	0.00105	CcSEcCtD
Brimonidine—Headache—Cladribine—multiple sclerosis	0.000666	0.00104	CcSEcCtD
Brimonidine—Arrhythmia—Triamcinolone—multiple sclerosis	0.000662	0.00104	CcSEcCtD
Brimonidine—Vision blurred—Prednisolone—multiple sclerosis	0.000662	0.00104	CcSEcCtD
Brimonidine—Arrhythmia—Methylprednisolone—multiple sclerosis	0.000661	0.00104	CcSEcCtD
Brimonidine—Hypotension—Mitoxantrone—multiple sclerosis	0.000653	0.00102	CcSEcCtD
Brimonidine—Depression—Prednisone—multiple sclerosis	0.000651	0.00102	CcSEcCtD
Brimonidine—Visual impairment—Betamethasone—multiple sclerosis	0.000648	0.00102	CcSEcCtD
Brimonidine—Visual impairment—Dexamethasone—multiple sclerosis	0.000648	0.00102	CcSEcCtD
Brimonidine—Mental disorder—Methylprednisolone—multiple sclerosis	0.000648	0.00102	CcSEcCtD
Brimonidine—Erythema—Triamcinolone—multiple sclerosis	0.000646	0.00101	CcSEcCtD
Brimonidine—Erythema—Methylprednisolone—multiple sclerosis	0.000644	0.00101	CcSEcCtD
Brimonidine—Hypersensitivity—Azathioprine—multiple sclerosis	0.000636	0.000998	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Mitoxantrone—multiple sclerosis	0.000636	0.000998	CcSEcCtD
Brimonidine—Dysgeusia—Triamcinolone—multiple sclerosis	0.000632	0.000992	CcSEcCtD
Brimonidine—Nausea—Cladribine—multiple sclerosis	0.000631	0.00099	CcSEcCtD
Brimonidine—Syncope—Prednisolone—multiple sclerosis	0.00063	0.000987	CcSEcCtD
Brimonidine—Eye disorder—Betamethasone—multiple sclerosis	0.000629	0.000986	CcSEcCtD
Brimonidine—Eye disorder—Dexamethasone—multiple sclerosis	0.000629	0.000986	CcSEcCtD
Brimonidine—Paraesthesia—Mitoxantrone—multiple sclerosis	0.000627	0.000984	CcSEcCtD
Brimonidine—Dyspnoea—Mitoxantrone—multiple sclerosis	0.000623	0.000977	CcSEcCtD
Brimonidine—Somnolence—Mitoxantrone—multiple sclerosis	0.000621	0.000974	CcSEcCtD
Brimonidine—Loss of consciousness—Prednisolone—multiple sclerosis	0.000617	0.000968	CcSEcCtD
Brimonidine—Dyspepsia—Mitoxantrone—multiple sclerosis	0.000615	0.000964	CcSEcCtD
Brimonidine—Angiopathy—Betamethasone—multiple sclerosis	0.00061	0.000958	CcSEcCtD
Brimonidine—Angiopathy—Dexamethasone—multiple sclerosis	0.00061	0.000958	CcSEcCtD
Brimonidine—Hypertension—Prednisolone—multiple sclerosis	0.000606	0.000951	CcSEcCtD
Brimonidine—Fatigue—Mitoxantrone—multiple sclerosis	0.000602	0.000944	CcSEcCtD
Brimonidine—Arrhythmia—Dexamethasone—multiple sclerosis	0.000601	0.000943	CcSEcCtD
Brimonidine—Arrhythmia—Betamethasone—multiple sclerosis	0.000601	0.000943	CcSEcCtD
Brimonidine—Pain—Mitoxantrone—multiple sclerosis	0.000597	0.000937	CcSEcCtD
Brimonidine—Bradycardia—Prednisone—multiple sclerosis	0.000597	0.000936	CcSEcCtD
Brimonidine—Discomfort—Prednisolone—multiple sclerosis	0.00059	0.000926	CcSEcCtD
Brimonidine—Erythema—Betamethasone—multiple sclerosis	0.000586	0.000919	CcSEcCtD
Brimonidine—Erythema—Dexamethasone—multiple sclerosis	0.000586	0.000919	CcSEcCtD
Brimonidine—Syncope—Triamcinolone—multiple sclerosis	0.000579	0.000908	CcSEcCtD
Brimonidine—Syncope—Methylprednisolone—multiple sclerosis	0.000578	0.000906	CcSEcCtD
Brimonidine—Oedema—Prednisolone—multiple sclerosis	0.000573	0.000899	CcSEcCtD
Brimonidine—Dizziness—Azathioprine—multiple sclerosis	0.000571	0.000896	CcSEcCtD
Brimonidine—Loss of consciousness—Triamcinolone—multiple sclerosis	0.000567	0.00089	CcSEcCtD
Brimonidine—Loss of consciousness—Methylprednisolone—multiple sclerosis	0.000566	0.000888	CcSEcCtD
Brimonidine—Shock—Prednisolone—multiple sclerosis	0.000564	0.000884	CcSEcCtD
Brimonidine—Cough—Triamcinolone—multiple sclerosis	0.000563	0.000884	CcSEcCtD
Brimonidine—Tachycardia—Prednisolone—multiple sclerosis	0.000559	0.000877	CcSEcCtD
Brimonidine—Hypertension—Triamcinolone—multiple sclerosis	0.000557	0.000874	CcSEcCtD
Brimonidine—Hypertension—Methylprednisolone—multiple sclerosis	0.000556	0.000872	CcSEcCtD
Brimonidine—Myalgia—Triamcinolone—multiple sclerosis	0.00055	0.000862	CcSEcCtD
Brimonidine—Myalgia—Methylprednisolone—multiple sclerosis	0.000548	0.00086	CcSEcCtD
Brimonidine—Arthralgia—Methylprednisolone—multiple sclerosis	0.000548	0.00086	CcSEcCtD
Brimonidine—Eye disorder—Prednisone—multiple sclerosis	0.000548	0.000859	CcSEcCtD
Brimonidine—Anxiety—Methylprednisolone—multiple sclerosis	0.000546	0.000857	CcSEcCtD
Brimonidine—Drowsiness—Methotrexate—multiple sclerosis	0.000546	0.000856	CcSEcCtD
Brimonidine—Rash—Azathioprine—multiple sclerosis	0.000545	0.000854	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.000545	0.000854	CcSEcCtD
Brimonidine—Dermatitis—Azathioprine—multiple sclerosis	0.000544	0.000854	CcSEcCtD
Brimonidine—Depression—Methotrexate—multiple sclerosis	0.000544	0.000853	CcSEcCtD
Brimonidine—Flushing—Prednisone—multiple sclerosis	0.000544	0.000853	CcSEcCtD
Brimonidine—Discomfort—Triamcinolone—multiple sclerosis	0.000543	0.000852	CcSEcCtD
Brimonidine—Discomfort—Methylprednisolone—multiple sclerosis	0.000542	0.00085	CcSEcCtD
Brimonidine—Headache—Azathioprine—multiple sclerosis	0.000541	0.000849	CcSEcCtD
Brimonidine—Dry mouth—Triamcinolone—multiple sclerosis	0.000538	0.000843	CcSEcCtD
Brimonidine—Angiopathy—Prednisone—multiple sclerosis	0.000532	0.000834	CcSEcCtD
Brimonidine—Conjunctivitis—Methotrexate—multiple sclerosis	0.00053	0.000832	CcSEcCtD
Brimonidine—Immune system disorder—Prednisone—multiple sclerosis	0.000529	0.00083	CcSEcCtD
Brimonidine—Oedema—Triamcinolone—multiple sclerosis	0.000527	0.000826	CcSEcCtD
Brimonidine—Syncope—Betamethasone—multiple sclerosis	0.000525	0.000824	CcSEcCtD
Brimonidine—Syncope—Dexamethasone—multiple sclerosis	0.000525	0.000824	CcSEcCtD
Brimonidine—Arrhythmia—Prednisone—multiple sclerosis	0.000523	0.000821	CcSEcCtD
Brimonidine—Infection—Triamcinolone—multiple sclerosis	0.000523	0.000821	CcSEcCtD
Brimonidine—Infection—Methylprednisolone—multiple sclerosis	0.000522	0.000819	CcSEcCtD
Brimonidine—Shock—Triamcinolone—multiple sclerosis	0.000518	0.000813	CcSEcCtD
Brimonidine—Insomnia—Prednisolone—multiple sclerosis	0.000518	0.000813	CcSEcCtD
Brimonidine—Shock—Methylprednisolone—multiple sclerosis	0.000517	0.000811	CcSEcCtD
Brimonidine—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.000516	0.000809	CcSEcCtD
Brimonidine—Loss of consciousness—Dexamethasone—multiple sclerosis	0.000515	0.000808	CcSEcCtD
Brimonidine—Loss of consciousness—Betamethasone—multiple sclerosis	0.000515	0.000808	CcSEcCtD
Brimonidine—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.000515	0.000807	CcSEcCtD
Brimonidine—Paraesthesia—Prednisolone—multiple sclerosis	0.000514	0.000807	CcSEcCtD
Brimonidine—Tachycardia—Triamcinolone—multiple sclerosis	0.000514	0.000807	CcSEcCtD
Brimonidine—Mental disorder—Prednisone—multiple sclerosis	0.000513	0.000805	CcSEcCtD
Brimonidine—Nausea—Azathioprine—multiple sclerosis	0.000513	0.000805	CcSEcCtD
Brimonidine—Tachycardia—Methylprednisolone—multiple sclerosis	0.000513	0.000805	CcSEcCtD
Brimonidine—Skin disorder—Methylprednisolone—multiple sclerosis	0.000511	0.000801	CcSEcCtD
Brimonidine—Erythema—Prednisone—multiple sclerosis	0.00051	0.0008	CcSEcCtD
Brimonidine—Hypertension—Betamethasone—multiple sclerosis	0.000506	0.000793	CcSEcCtD
Brimonidine—Hypertension—Dexamethasone—multiple sclerosis	0.000506	0.000793	CcSEcCtD
Brimonidine—Asthenia—Mitoxantrone—multiple sclerosis	0.000501	0.000786	CcSEcCtD
Brimonidine—Myalgia—Betamethasone—multiple sclerosis	0.000499	0.000782	CcSEcCtD
Brimonidine—Myalgia—Dexamethasone—multiple sclerosis	0.000499	0.000782	CcSEcCtD
Brimonidine—Anxiety—Betamethasone—multiple sclerosis	0.000497	0.000779	CcSEcCtD
Brimonidine—Anxiety—Dexamethasone—multiple sclerosis	0.000497	0.000779	CcSEcCtD
Brimonidine—Discomfort—Betamethasone—multiple sclerosis	0.000493	0.000773	CcSEcCtD
Brimonidine—Discomfort—Dexamethasone—multiple sclerosis	0.000493	0.000773	CcSEcCtD
Brimonidine—Hypotension—Methylprednisolone—multiple sclerosis	0.000491	0.00077	CcSEcCtD
Brimonidine—Pain—Prednisolone—multiple sclerosis	0.00049	0.000768	CcSEcCtD
Brimonidine—Pharyngitis—Methotrexate—multiple sclerosis	0.000486	0.000762	CcSEcCtD
Brimonidine—Vision blurred—Prednisone—multiple sclerosis	0.000481	0.000754	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.00048	0.000753	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.000479	0.000751	CcSEcCtD
Brimonidine—Oedema—Dexamethasone—multiple sclerosis	0.000478	0.00075	CcSEcCtD
Brimonidine—Oedema—Betamethasone—multiple sclerosis	0.000478	0.00075	CcSEcCtD
Brimonidine—Insomnia—Triamcinolone—multiple sclerosis	0.000477	0.000747	CcSEcCtD
Brimonidine—Insomnia—Methylprednisolone—multiple sclerosis	0.000475	0.000746	CcSEcCtD
Brimonidine—Infection—Betamethasone—multiple sclerosis	0.000475	0.000745	CcSEcCtD
Brimonidine—Infection—Dexamethasone—multiple sclerosis	0.000475	0.000745	CcSEcCtD
Brimonidine—Paraesthesia—Triamcinolone—multiple sclerosis	0.000473	0.000742	CcSEcCtD
Brimonidine—Paraesthesia—Methylprednisolone—multiple sclerosis	0.000472	0.00074	CcSEcCtD
Brimonidine—Visual impairment—Methotrexate—multiple sclerosis	0.000472	0.00074	CcSEcCtD
Brimonidine—Shock—Betamethasone—multiple sclerosis	0.00047	0.000738	CcSEcCtD
Brimonidine—Shock—Dexamethasone—multiple sclerosis	0.00047	0.000738	CcSEcCtD
Brimonidine—Dyspnoea—Triamcinolone—multiple sclerosis	0.00047	0.000737	CcSEcCtD
Brimonidine—Nervous system disorder—Betamethasone—multiple sclerosis	0.000469	0.000735	CcSEcCtD
Brimonidine—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000469	0.000735	CcSEcCtD
Brimonidine—Tachycardia—Betamethasone—multiple sclerosis	0.000467	0.000732	CcSEcCtD
Brimonidine—Tachycardia—Dexamethasone—multiple sclerosis	0.000467	0.000732	CcSEcCtD
Brimonidine—Dyspepsia—Triamcinolone—multiple sclerosis	0.000464	0.000727	CcSEcCtD
Brimonidine—Dyspepsia—Methylprednisolone—multiple sclerosis	0.000463	0.000726	CcSEcCtD
Brimonidine—Eye disorder—Methotrexate—multiple sclerosis	0.000458	0.000718	CcSEcCtD
Brimonidine—Syncope—Prednisone—multiple sclerosis	0.000457	0.000718	CcSEcCtD
Brimonidine—Cardiac disorder—Methotrexate—multiple sclerosis	0.000455	0.000713	CcSEcCtD
Brimonidine—Fatigue—Triamcinolone—multiple sclerosis	0.000454	0.000712	CcSEcCtD
Brimonidine—Fatigue—Methylprednisolone—multiple sclerosis	0.000453	0.000711	CcSEcCtD
Brimonidine—Pain—Triamcinolone—multiple sclerosis	0.000451	0.000707	CcSEcCtD
Brimonidine—Loss of consciousness—Prednisone—multiple sclerosis	0.000448	0.000703	CcSEcCtD
Brimonidine—Hypotension—Betamethasone—multiple sclerosis	0.000447	0.000701	CcSEcCtD
Brimonidine—Hypotension—Dexamethasone—multiple sclerosis	0.000447	0.000701	CcSEcCtD
Brimonidine—Angiopathy—Methotrexate—multiple sclerosis	0.000444	0.000697	CcSEcCtD
Brimonidine—Immune system disorder—Methotrexate—multiple sclerosis	0.000442	0.000694	CcSEcCtD
Brimonidine—Mediastinal disorder—Methotrexate—multiple sclerosis	0.000441	0.000692	CcSEcCtD
Brimonidine—Hypertension—Prednisone—multiple sclerosis	0.00044	0.000691	CcSEcCtD
Brimonidine—Rash—Mitoxantrone—multiple sclerosis	0.00044	0.000691	CcSEcCtD
Brimonidine—Dermatitis—Mitoxantrone—multiple sclerosis	0.00044	0.00069	CcSEcCtD
Brimonidine—Headache—Mitoxantrone—multiple sclerosis	0.000437	0.000686	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.000436	0.000683	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.000436	0.000683	CcSEcCtD
Brimonidine—Myalgia—Prednisone—multiple sclerosis	0.000434	0.000681	CcSEcCtD
Brimonidine—Arthralgia—Prednisone—multiple sclerosis	0.000434	0.000681	CcSEcCtD
Brimonidine—Anxiety—Prednisone—multiple sclerosis	0.000433	0.000679	CcSEcCtD
Brimonidine—Insomnia—Betamethasone—multiple sclerosis	0.000432	0.000678	CcSEcCtD
Brimonidine—Insomnia—Dexamethasone—multiple sclerosis	0.000432	0.000678	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000431	0.000676	CcSEcCtD
Brimonidine—Paraesthesia—Betamethasone—multiple sclerosis	0.000429	0.000673	CcSEcCtD
Brimonidine—Paraesthesia—Dexamethasone—multiple sclerosis	0.000429	0.000673	CcSEcCtD
Brimonidine—Discomfort—Prednisone—multiple sclerosis	0.000429	0.000673	CcSEcCtD
Brimonidine—Mental disorder—Methotrexate—multiple sclerosis	0.000429	0.000673	CcSEcCtD
Brimonidine—Erythema—Methotrexate—multiple sclerosis	0.000426	0.000669	CcSEcCtD
Brimonidine—Hypersensitivity—Prednisolone—multiple sclerosis	0.000422	0.000662	CcSEcCtD
Brimonidine—Dyspepsia—Betamethasone—multiple sclerosis	0.000421	0.00066	CcSEcCtD
Brimonidine—Dyspepsia—Dexamethasone—multiple sclerosis	0.000421	0.00066	CcSEcCtD
Brimonidine—Dysgeusia—Methotrexate—multiple sclerosis	0.000417	0.000655	CcSEcCtD
Brimonidine—Oedema—Prednisone—multiple sclerosis	0.000416	0.000653	CcSEcCtD
Brimonidine—Nausea—Mitoxantrone—multiple sclerosis	0.000415	0.000651	CcSEcCtD
Brimonidine—Infection—Prednisone—multiple sclerosis	0.000414	0.000649	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000413	0.000647	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000413	0.000647	CcSEcCtD
Brimonidine—Fatigue—Dexamethasone—multiple sclerosis	0.000412	0.000646	CcSEcCtD
Brimonidine—Fatigue—Betamethasone—multiple sclerosis	0.000412	0.000646	CcSEcCtD
Brimonidine—Shock—Prednisone—multiple sclerosis	0.00041	0.000642	CcSEcCtD
Brimonidine—Pain—Dexamethasone—multiple sclerosis	0.000409	0.000641	CcSEcCtD
Brimonidine—Pain—Betamethasone—multiple sclerosis	0.000409	0.000641	CcSEcCtD
Brimonidine—Nervous system disorder—Prednisone—multiple sclerosis	0.000408	0.00064	CcSEcCtD
Brimonidine—Tachycardia—Prednisone—multiple sclerosis	0.000406	0.000637	CcSEcCtD
Brimonidine—Skin disorder—Prednisone—multiple sclerosis	0.000404	0.000634	CcSEcCtD
Brimonidine—Vision blurred—Methotrexate—multiple sclerosis	0.000402	0.00063	CcSEcCtD
Brimonidine—Hypersensitivity—Triamcinolone—multiple sclerosis	0.000388	0.000609	CcSEcCtD
Brimonidine—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.000387	0.000607	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Prednisone—multiple sclerosis	0.000379	0.000595	CcSEcCtD
Brimonidine—Dizziness—Prednisolone—multiple sclerosis	0.000379	0.000594	CcSEcCtD
Brimonidine—Asthenia—Triamcinolone—multiple sclerosis	0.000378	0.000593	CcSEcCtD
Brimonidine—Asthenia—Methylprednisolone—multiple sclerosis	0.000377	0.000592	CcSEcCtD
Brimonidine—Insomnia—Prednisone—multiple sclerosis	0.000377	0.000591	CcSEcCtD
Brimonidine—Paraesthesia—Prednisone—multiple sclerosis	0.000374	0.000586	CcSEcCtD
Brimonidine—Pruritus—Triamcinolone—multiple sclerosis	0.000373	0.000585	CcSEcCtD
Brimonidine—Cough—Methotrexate—multiple sclerosis	0.000372	0.000584	CcSEcCtD
Brimonidine—Pruritus—Methylprednisolone—multiple sclerosis	0.000372	0.000583	CcSEcCtD
Brimonidine—Dyspepsia—Prednisone—multiple sclerosis	0.000366	0.000575	CcSEcCtD
Brimonidine—Myalgia—Methotrexate—multiple sclerosis	0.000363	0.000569	CcSEcCtD
Brimonidine—Chest pain—Methotrexate—multiple sclerosis	0.000363	0.000569	CcSEcCtD
Brimonidine—Arthralgia—Methotrexate—multiple sclerosis	0.000363	0.000569	CcSEcCtD
Brimonidine—Rash—Prednisolone—multiple sclerosis	0.000361	0.000567	CcSEcCtD
Brimonidine—Dermatitis—Prednisolone—multiple sclerosis	0.000361	0.000566	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.00036	0.000565	CcSEcCtD
Brimonidine—Fatigue—Prednisone—multiple sclerosis	0.000359	0.000563	CcSEcCtD
Brimonidine—Headache—Prednisolone—multiple sclerosis	0.000359	0.000563	CcSEcCtD
Brimonidine—Discomfort—Methotrexate—multiple sclerosis	0.000359	0.000562	CcSEcCtD
Brimonidine—Dizziness—Triamcinolone—multiple sclerosis	0.000348	0.000546	CcSEcCtD
Brimonidine—Dizziness—Methylprednisolone—multiple sclerosis	0.000348	0.000545	CcSEcCtD
Brimonidine—Infection—Methotrexate—multiple sclerosis	0.000346	0.000542	CcSEcCtD
Brimonidine—Asthenia—Betamethasone—multiple sclerosis	0.000343	0.000538	CcSEcCtD
Brimonidine—Asthenia—Dexamethasone—multiple sclerosis	0.000343	0.000538	CcSEcCtD
Brimonidine—Nervous system disorder—Methotrexate—multiple sclerosis	0.000341	0.000535	CcSEcCtD
Brimonidine—Nausea—Prednisolone—multiple sclerosis	0.00034	0.000534	CcSEcCtD
Brimonidine—Pruritus—Betamethasone—multiple sclerosis	0.000338	0.00053	CcSEcCtD
Brimonidine—Pruritus—Dexamethasone—multiple sclerosis	0.000338	0.00053	CcSEcCtD
Brimonidine—Skin disorder—Methotrexate—multiple sclerosis	0.000338	0.00053	CcSEcCtD
Brimonidine—Rash—Triamcinolone—multiple sclerosis	0.000332	0.000521	CcSEcCtD
Brimonidine—Dermatitis—Triamcinolone—multiple sclerosis	0.000332	0.000521	CcSEcCtD
Brimonidine—Rash—Methylprednisolone—multiple sclerosis	0.000331	0.00052	CcSEcCtD
Brimonidine—Dermatitis—Methylprednisolone—multiple sclerosis	0.000331	0.000519	CcSEcCtD
Brimonidine—Headache—Triamcinolone—multiple sclerosis	0.00033	0.000518	CcSEcCtD
Brimonidine—Headache—Methylprednisolone—multiple sclerosis	0.000329	0.000517	CcSEcCtD
Brimonidine—Hypotension—Methotrexate—multiple sclerosis	0.000325	0.00051	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	0.000317	0.000497	CcSEcCtD
Brimonidine—Dizziness—Dexamethasone—multiple sclerosis	0.000316	0.000496	CcSEcCtD
Brimonidine—Dizziness—Betamethasone—multiple sclerosis	0.000316	0.000496	CcSEcCtD
Brimonidine—Insomnia—Methotrexate—multiple sclerosis	0.000315	0.000494	CcSEcCtD
Brimonidine—Nausea—Triamcinolone—multiple sclerosis	0.000313	0.000491	CcSEcCtD
Brimonidine—Paraesthesia—Methotrexate—multiple sclerosis	0.000312	0.00049	CcSEcCtD
Brimonidine—Nausea—Methylprednisolone—multiple sclerosis	0.000312	0.00049	CcSEcCtD
Brimonidine—Dyspnoea—Methotrexate—multiple sclerosis	0.00031	0.000487	CcSEcCtD
Brimonidine—Somnolence—Methotrexate—multiple sclerosis	0.000309	0.000485	CcSEcCtD
Brimonidine—Hypersensitivity—Prednisone—multiple sclerosis	0.000307	0.000481	CcSEcCtD
Brimonidine—Dyspepsia—Methotrexate—multiple sclerosis	0.000306	0.00048	CcSEcCtD
Brimonidine—Rash—Dexamethasone—multiple sclerosis	0.000301	0.000473	CcSEcCtD
Brimonidine—Rash—Betamethasone—multiple sclerosis	0.000301	0.000473	CcSEcCtD
Brimonidine—Dermatitis—Dexamethasone—multiple sclerosis	0.000301	0.000472	CcSEcCtD
Brimonidine—Dermatitis—Betamethasone—multiple sclerosis	0.000301	0.000472	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.0003	0.000471	CcSEcCtD
Brimonidine—Fatigue—Methotrexate—multiple sclerosis	0.0003	0.000471	CcSEcCtD
Brimonidine—Headache—Dexamethasone—multiple sclerosis	0.000299	0.00047	CcSEcCtD
Brimonidine—Headache—Betamethasone—multiple sclerosis	0.000299	0.00047	CcSEcCtD
Brimonidine—Asthenia—Prednisone—multiple sclerosis	0.000299	0.000469	CcSEcCtD
Brimonidine—Pain—Methotrexate—multiple sclerosis	0.000298	0.000467	CcSEcCtD
Brimonidine—Pruritus—Prednisone—multiple sclerosis	0.000295	0.000462	CcSEcCtD
Brimonidine—Nausea—Dexamethasone—multiple sclerosis	0.000284	0.000445	CcSEcCtD
Brimonidine—Nausea—Betamethasone—multiple sclerosis	0.000284	0.000445	CcSEcCtD
Brimonidine—Dizziness—Prednisone—multiple sclerosis	0.000275	0.000432	CcSEcCtD
Brimonidine—Rash—Prednisone—multiple sclerosis	0.000262	0.000412	CcSEcCtD
Brimonidine—Dermatitis—Prednisone—multiple sclerosis	0.000262	0.000411	CcSEcCtD
Brimonidine—Headache—Prednisone—multiple sclerosis	0.000261	0.000409	CcSEcCtD
Brimonidine—Hypersensitivity—Methotrexate—multiple sclerosis	0.000256	0.000402	CcSEcCtD
Brimonidine—Asthenia—Methotrexate—multiple sclerosis	0.00025	0.000392	CcSEcCtD
Brimonidine—Nausea—Prednisone—multiple sclerosis	0.000247	0.000388	CcSEcCtD
Brimonidine—Pruritus—Methotrexate—multiple sclerosis	0.000246	0.000386	CcSEcCtD
Brimonidine—Dizziness—Methotrexate—multiple sclerosis	0.00023	0.000361	CcSEcCtD
Brimonidine—Rash—Methotrexate—multiple sclerosis	0.000219	0.000344	CcSEcCtD
Brimonidine—Dermatitis—Methotrexate—multiple sclerosis	0.000219	0.000344	CcSEcCtD
Brimonidine—Headache—Methotrexate—multiple sclerosis	0.000218	0.000342	CcSEcCtD
Brimonidine—Nausea—Methotrexate—multiple sclerosis	0.000207	0.000324	CcSEcCtD
Brimonidine—AOX1—Disease—CD86—multiple sclerosis	2.94e-05	0.00194	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR ligand binding—CCL5—multiple sclerosis	2.92e-05	0.00193	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—CXCL13—multiple sclerosis	2.91e-05	0.00192	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—CCR1—multiple sclerosis	2.91e-05	0.00192	CbGpPWpGaD
Brimonidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	2.89e-05	0.00191	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—GPR65—multiple sclerosis	2.89e-05	0.00191	CbGpPWpGaD
Brimonidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	2.83e-05	0.00187	CbGpPWpGaD
Brimonidine—ADRA2B—Platelet activation, signaling and aggregation—IL2—multiple sclerosis	2.82e-05	0.00186	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR ligand binding—CCR5—multiple sclerosis	2.82e-05	0.00186	CbGpPWpGaD
Brimonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CCR5—multiple sclerosis	2.8e-05	0.00185	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—LINGO1—multiple sclerosis	2.79e-05	0.00184	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—S1PR1—multiple sclerosis	2.79e-05	0.00184	CbGpPWpGaD
Brimonidine—ADRA2A—G alpha (i) signalling events—POMC—multiple sclerosis	2.76e-05	0.00182	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—ITGA4—multiple sclerosis	2.76e-05	0.00182	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR ligand binding—CXCL10—multiple sclerosis	2.75e-05	0.00182	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—IFNB1—multiple sclerosis	2.74e-05	0.00181	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—GPC5—multiple sclerosis	2.71e-05	0.00179	CbGpPWpGaD
Brimonidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	2.7e-05	0.00178	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—CYP27B1—multiple sclerosis	2.69e-05	0.00178	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—CYP24A1—multiple sclerosis	2.69e-05	0.00178	CbGpPWpGaD
Brimonidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	2.64e-05	0.00174	CbGpPWpGaD
Brimonidine—ADRA2A—Platelet activation, signaling and aggregation—ALB—multiple sclerosis	2.64e-05	0.00174	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—CXCL13—multiple sclerosis	2.64e-05	0.00174	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—CCR1—multiple sclerosis	2.64e-05	0.00174	CbGpPWpGaD
Brimonidine—ADRA2C—Platelet activation, signaling and aggregation—IL2—multiple sclerosis	2.64e-05	0.00174	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR ligand binding—CCR5—multiple sclerosis	2.63e-05	0.00174	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—PTGER4—multiple sclerosis	2.63e-05	0.00173	CbGpPWpGaD
Brimonidine—AOX1—Disease—CCR5—multiple sclerosis	2.61e-05	0.00172	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—S1PR1—multiple sclerosis	2.6e-05	0.00172	CbGpPWpGaD
Brimonidine—AOX1—Disease—HLA-A—multiple sclerosis	2.54e-05	0.00168	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—CXCR3—multiple sclerosis	2.54e-05	0.00168	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—GPC5—multiple sclerosis	2.53e-05	0.00167	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—RRM1—multiple sclerosis	2.51e-05	0.00166	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—IL2RA—multiple sclerosis	2.48e-05	0.00164	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—CCL3—multiple sclerosis	2.48e-05	0.00164	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—CCR2—multiple sclerosis	2.47e-05	0.00163	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—GPC5—multiple sclerosis	2.46e-05	0.00162	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—PTGER4—multiple sclerosis	2.45e-05	0.00162	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—TAGAP—multiple sclerosis	2.42e-05	0.0016	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—PTGER4—multiple sclerosis	2.39e-05	0.00158	CbGpPWpGaD
Brimonidine—AOX1—Disease—APOE—multiple sclerosis	2.37e-05	0.00157	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR ligand binding—CCL5—multiple sclerosis	2.37e-05	0.00156	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—CXCR3—multiple sclerosis	2.37e-05	0.00156	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—RGS1—multiple sclerosis	2.37e-05	0.00156	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—IL2RA—multiple sclerosis	2.32e-05	0.00153	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—CCL3—multiple sclerosis	2.32e-05	0.00153	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—CCR2—multiple sclerosis	2.31e-05	0.00152	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—CXCR3—multiple sclerosis	2.3e-05	0.00152	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—CNR1—multiple sclerosis	2.28e-05	0.0015	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—GPR65—multiple sclerosis	2.25e-05	0.00148	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—CCR2—multiple sclerosis	2.24e-05	0.00148	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—PTGER4—multiple sclerosis	2.23e-05	0.00147	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—RGS1—multiple sclerosis	2.21e-05	0.00146	CbGpPWpGaD
Brimonidine—ADRA2B—Platelet activation, signaling and aggregation—TGFB1—multiple sclerosis	2.2e-05	0.00145	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR ligand binding—POMC—multiple sclerosis	2.2e-05	0.00145	CbGpPWpGaD
Brimonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	2.19e-05	0.00145	CbGpPWpGaD
Brimonidine—ADRA2B—Platelet activation, signaling and aggregation—MAPK1—multiple sclerosis	2.16e-05	0.00142	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—CXCR3—multiple sclerosis	2.15e-05	0.00142	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR ligand binding—CCL2—multiple sclerosis	2.15e-05	0.00142	CbGpPWpGaD
Brimonidine—AOX1—Disease—CD80—multiple sclerosis	2.15e-05	0.00142	CbGpPWpGaD
Brimonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	2.14e-05	0.00142	CbGpPWpGaD
Brimonidine—ADRA2A—Platelet activation, signaling and aggregation—IL2—multiple sclerosis	2.14e-05	0.00141	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR ligand binding—CCR5—multiple sclerosis	2.14e-05	0.00141	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—CNR1—multiple sclerosis	2.13e-05	0.0014	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—S1PR1—multiple sclerosis	2.12e-05	0.0014	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—GPR65—multiple sclerosis	2.1e-05	0.00139	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—CCR2—multiple sclerosis	2.09e-05	0.00138	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—CNR1—multiple sclerosis	2.07e-05	0.00137	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—GPC5—multiple sclerosis	2.06e-05	0.00136	CbGpPWpGaD
Brimonidine—ADRA2C—Platelet activation, signaling and aggregation—TGFB1—multiple sclerosis	2.06e-05	0.00136	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CCR1—multiple sclerosis	2.06e-05	0.00136	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CXCL13—multiple sclerosis	2.06e-05	0.00136	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR ligand binding—POMC—multiple sclerosis	2.06e-05	0.00136	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—CXCL10—multiple sclerosis	2.05e-05	0.00135	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—RRM1—multiple sclerosis	2.04e-05	0.00135	CbGpPWpGaD
Brimonidine—ADRA2C—Platelet activation, signaling and aggregation—MAPK1—multiple sclerosis	2.02e-05	0.00133	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR ligand binding—CCL2—multiple sclerosis	2.01e-05	0.00133	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—PTGER4—multiple sclerosis	1.99e-05	0.00132	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—APOE—multiple sclerosis	1.99e-05	0.00131	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—CNR1—multiple sclerosis	1.93e-05	0.00128	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—CXCR3—multiple sclerosis	1.93e-05	0.00127	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CXCL13—multiple sclerosis	1.92e-05	0.00127	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CCR1—multiple sclerosis	1.92e-05	0.00127	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—CXCL10—multiple sclerosis	1.92e-05	0.00126	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—IL2RA—multiple sclerosis	1.88e-05	0.00124	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—CCL3—multiple sclerosis	1.88e-05	0.00124	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—CCR2—multiple sclerosis	1.87e-05	0.00124	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—CXCL10—multiple sclerosis	1.86e-05	0.00123	CbGpPWpGaD
Brimonidine—AOX1—Disease—TYK2—multiple sclerosis	1.81e-05	0.0012	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—PTGER4—multiple sclerosis	1.81e-05	0.0012	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—RGS1—multiple sclerosis	1.8e-05	0.00119	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—ALB—multiple sclerosis	1.79e-05	0.00118	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—CCL5—multiple sclerosis	1.77e-05	0.00117	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—CXCR3—multiple sclerosis	1.75e-05	0.00115	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—CXCL10—multiple sclerosis	1.74e-05	0.00115	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—CNR1—multiple sclerosis	1.73e-05	0.00114	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—POMC—multiple sclerosis	1.71e-05	0.00113	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—GPR65—multiple sclerosis	1.7e-05	0.00113	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—CCR2—multiple sclerosis	1.7e-05	0.00112	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—ALB—multiple sclerosis	1.68e-05	0.00111	CbGpPWpGaD
Brimonidine—ADRA2A—Platelet activation, signaling and aggregation—TGFB1—multiple sclerosis	1.67e-05	0.0011	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR ligand binding—POMC—multiple sclerosis	1.67e-05	0.0011	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—CCL5—multiple sclerosis	1.65e-05	0.00109	CbGpPWpGaD
Brimonidine—AOX1—Disease—CD4—multiple sclerosis	1.64e-05	0.00108	CbGpPWpGaD
Brimonidine—ADRA2A—Platelet activation, signaling and aggregation—MAPK1—multiple sclerosis	1.64e-05	0.00108	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR ligand binding—CCL2—multiple sclerosis	1.63e-05	0.00108	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—CCL5—multiple sclerosis	1.6e-05	0.00106	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—CCR5—multiple sclerosis	1.59e-05	0.00105	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—CNR1—multiple sclerosis	1.57e-05	0.00104	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—IL2RA—multiple sclerosis	1.57e-05	0.00103	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CCR1—multiple sclerosis	1.56e-05	0.00103	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CXCL13—multiple sclerosis	1.56e-05	0.00103	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—ALB—multiple sclerosis	1.56e-05	0.00103	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—CXCL10—multiple sclerosis	1.56e-05	0.00103	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—CCL5—multiple sclerosis	1.5e-05	0.000989	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—CCR5—multiple sclerosis	1.49e-05	0.000981	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—IL2RA—multiple sclerosis	1.46e-05	0.000967	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CCL3—multiple sclerosis	1.46e-05	0.000967	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—IL2—multiple sclerosis	1.45e-05	0.00096	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—CCR5—multiple sclerosis	1.44e-05	0.000954	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—BCHE—multiple sclerosis	1.44e-05	0.000952	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—IL2RA—multiple sclerosis	1.42e-05	0.00094	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—CXCL10—multiple sclerosis	1.41e-05	0.000933	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PTGER4—multiple sclerosis	1.41e-05	0.000931	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PGR—multiple sclerosis	1.39e-05	0.000916	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CCL3—multiple sclerosis	1.37e-05	0.000903	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CXCR3—multiple sclerosis	1.36e-05	0.000899	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—ALB—multiple sclerosis	1.36e-05	0.000898	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—IL2—multiple sclerosis	1.36e-05	0.000897	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—CCR5—multiple sclerosis	1.35e-05	0.000891	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CD28—multiple sclerosis	1.35e-05	0.00089	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—CCL5—multiple sclerosis	1.34e-05	0.000884	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—IL2RA—multiple sclerosis	1.33e-05	0.000878	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CCR2—multiple sclerosis	1.32e-05	0.000874	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PTGER4—multiple sclerosis	1.32e-05	0.000869	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PGR—multiple sclerosis	1.3e-05	0.000856	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CXCR3—multiple sclerosis	1.27e-05	0.000839	CbGpPWpGaD
Brimonidine—AOX1—Disease—STAT3—multiple sclerosis	1.27e-05	0.000838	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CD28—multiple sclerosis	1.26e-05	0.000832	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—POMC—multiple sclerosis	1.24e-05	0.000821	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CCR2—multiple sclerosis	1.24e-05	0.000817	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CNR1—multiple sclerosis	1.22e-05	0.000807	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—CCL5—multiple sclerosis	1.22e-05	0.000803	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—CCR5—multiple sclerosis	1.21e-05	0.000797	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—IL2RA—multiple sclerosis	1.19e-05	0.000785	CbGpPWpGaD
Brimonidine—AOX1—Disease—MYC—multiple sclerosis	1.18e-05	0.000778	CbGpPWpGaD
Brimonidine—AOX1—Disease—TGFB1—multiple sclerosis	1.18e-05	0.000777	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—BCHE—multiple sclerosis	1.17e-05	0.000773	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—POMC—multiple sclerosis	1.16e-05	0.000767	CbGpPWpGaD
Brimonidine—AOX1—Disease—MAPK1—multiple sclerosis	1.15e-05	0.000762	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CNR1—multiple sclerosis	1.14e-05	0.000754	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—TGFB1—multiple sclerosis	1.13e-05	0.000749	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—POMC—multiple sclerosis	1.13e-05	0.000745	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—MAPK1—multiple sclerosis	1.11e-05	0.000734	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CCL3—multiple sclerosis	1.11e-05	0.000733	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—CCL2—multiple sclerosis	1.1e-05	0.000729	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—IL2—multiple sclerosis	1.1e-05	0.000728	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CXCL10—multiple sclerosis	1.1e-05	0.000726	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—CCR5—multiple sclerosis	1.1e-05	0.000724	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—IL2RA—multiple sclerosis	1.08e-05	0.000713	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PTGER4—multiple sclerosis	1.07e-05	0.000706	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—TGFB1—multiple sclerosis	1.06e-05	0.0007	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—POMC—multiple sclerosis	1.05e-05	0.000696	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PGR—multiple sclerosis	1.05e-05	0.000695	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—MAPK1—multiple sclerosis	1.04e-05	0.000686	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CXCR3—multiple sclerosis	1.03e-05	0.000682	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—CCL2—multiple sclerosis	1.03e-05	0.000681	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CXCL10—multiple sclerosis	1.03e-05	0.000679	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CD28—multiple sclerosis	1.02e-05	0.000675	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CCR2—multiple sclerosis	1e-05	0.000663	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—TYK2—multiple sclerosis	1e-05	0.000662	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CD86—multiple sclerosis	9.62e-06	0.000635	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CCL5—multiple sclerosis	9.47e-06	0.000625	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—POMC—multiple sclerosis	9.43e-06	0.000623	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—TYK2—multiple sclerosis	9.37e-06	0.000619	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CNR1—multiple sclerosis	9.27e-06	0.000612	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—IL2—multiple sclerosis	9.19e-06	0.000607	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CD86—multiple sclerosis	8.99e-06	0.000593	CbGpPWpGaD
Brimonidine—AOX1—Disease—IL6—multiple sclerosis	8.87e-06	0.000585	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CCL5—multiple sclerosis	8.85e-06	0.000584	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—SPP1—multiple sclerosis	8.77e-06	0.000579	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—APOE—multiple sclerosis	8.67e-06	0.000573	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—TGFB1—multiple sclerosis	8.61e-06	0.000568	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—IL2—multiple sclerosis	8.59e-06	0.000567	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—POMC—multiple sclerosis	8.57e-06	0.000565	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CCR5—multiple sclerosis	8.53e-06	0.000563	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—MAPK1—multiple sclerosis	8.44e-06	0.000557	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—IL2RA—multiple sclerosis	8.41e-06	0.000555	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—CCL2—multiple sclerosis	8.38e-06	0.000553	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CXCL10—multiple sclerosis	8.35e-06	0.000551	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—IL2—multiple sclerosis	8.35e-06	0.000551	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—SPP1—multiple sclerosis	8.2e-06	0.000541	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CCR5—multiple sclerosis	7.97e-06	0.000526	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—IL2RA—multiple sclerosis	7.86e-06	0.000519	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—IL2—multiple sclerosis	7.8e-06	0.000515	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—APOE—multiple sclerosis	7.76e-06	0.000513	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—TYK2—multiple sclerosis	7.61e-06	0.000502	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—POMC—multiple sclerosis	7.45e-06	0.000492	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CD86—multiple sclerosis	7.3e-06	0.000482	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—APOE—multiple sclerosis	7.25e-06	0.000479	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CCL5—multiple sclerosis	7.19e-06	0.000474	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—APOE—multiple sclerosis	7.05e-06	0.000465	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CD80—multiple sclerosis	7.02e-06	0.000463	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—IL2—multiple sclerosis	6.97e-06	0.00046	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—ALB—multiple sclerosis	6.79e-06	0.000448	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—POMC—multiple sclerosis	6.67e-06	0.00044	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—SPP1—multiple sclerosis	6.66e-06	0.000439	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CD80—multiple sclerosis	6.56e-06	0.000433	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CCL2—multiple sclerosis	6.53e-06	0.000431	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CCR5—multiple sclerosis	6.48e-06	0.000427	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—MAPK1—multiple sclerosis	6.39e-06	0.000421	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—IL2RA—multiple sclerosis	6.38e-06	0.000421	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—IL2—multiple sclerosis	6.33e-06	0.000418	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—POMC—multiple sclerosis	6.23e-06	0.000411	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CCL2—multiple sclerosis	6.1e-06	0.000402	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—POMC—multiple sclerosis	6.05e-06	0.0004	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—MAPK1—multiple sclerosis	5.96e-06	0.000394	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—TYK2—multiple sclerosis	5.93e-06	0.000391	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—APOE—multiple sclerosis	5.89e-06	0.000389	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—TYK2—multiple sclerosis	5.54e-06	0.000365	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—ALB—multiple sclerosis	5.52e-06	0.000364	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CD80—multiple sclerosis	5.33e-06	0.000352	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—POMC—multiple sclerosis	5.06e-06	0.000334	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CCL2—multiple sclerosis	4.95e-06	0.000327	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—IL2—multiple sclerosis	4.93e-06	0.000325	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—IL6—multiple sclerosis	4.91e-06	0.000324	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—MAPK1—multiple sclerosis	4.84e-06	0.00032	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—MMP9—multiple sclerosis	4.67e-06	0.000308	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—IL2—multiple sclerosis	4.61e-06	0.000304	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—IL6—multiple sclerosis	4.58e-06	0.000303	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—TYK2—multiple sclerosis	4.5e-06	0.000297	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—MMP9—multiple sclerosis	4.36e-06	0.000288	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—STAT3—multiple sclerosis	4.15e-06	0.000274	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—STAT3—multiple sclerosis	3.88e-06	0.000256	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—MYC—multiple sclerosis	3.86e-06	0.000255	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—TGFB1—multiple sclerosis	3.85e-06	0.000254	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—MAPK1—multiple sclerosis	3.77e-06	0.000249	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—IL2—multiple sclerosis	3.74e-06	0.000247	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—IL6—multiple sclerosis	3.72e-06	0.000246	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—MYC—multiple sclerosis	3.6e-06	0.000238	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—TGFB1—multiple sclerosis	3.59e-06	0.000237	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—MMP9—multiple sclerosis	3.54e-06	0.000234	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—MAPK1—multiple sclerosis	3.52e-06	0.000233	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—STAT3—multiple sclerosis	3.15e-06	0.000208	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—MYC—multiple sclerosis	2.93e-06	0.000193	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—TGFB1—multiple sclerosis	2.92e-06	0.000193	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—IL6—multiple sclerosis	2.9e-06	0.000191	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—MAPK1—multiple sclerosis	2.86e-06	0.000189	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—IL6—multiple sclerosis	2.71e-06	0.000179	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—IL6—multiple sclerosis	2.2e-06	0.000145	CbGpPWpGaD
